Stimulates LH, FSH and downstream sex hormones in humans [2]
Reproducibly demonstrated across human studies in men and women — the core pharmacological effect, well established.
PrecisePep/Peptide Library/Kisspeptin-10
Endocrine & Reproductive Axis
Kisspeptin-10
KP-10 · metastin(45-54) · KISS1 gene product
The master switch upstream of the entire reproductive axis — the signal that starts puberty, and one of the few compounds here with a genuine and active human research programme behind it.
00 Overview
Kisspeptin sits at the very top of the reproductive hormone cascade. Its discovery was a genuine landmark: loss-of-function mutations in GPR54 were found to cause hypogonadotropic hypogonadism and failure of puberty, which established kisspeptin signalling as the obligatory upstream trigger for GnRH release. Everything downstream — LH, FSH, testosterone, oestrogen — depends on it.[1]
Unlike most of this library, kisspeptin has a serious and continuing human research programme, much of it from Imperial College London, covering reproductive disorders, hypoactive sexual desire, IVF trigger protocols and the neural correlates of sexual and emotional processing.[2][3] Kisspeptin has been used as an alternative ovulation trigger in IVF with a favourable ovarian hyperstimulation profile — a real clinical application.
What shapes practical use is the half-life: about four minutes. Kisspeptin-10 is cleared almost immediately. Human studies overwhelmingly use intravenous infusion for exactly that reason. A subcutaneous bolus produces a brief pulse, which may be the point — or may be why community reports are so inconsistent.
Pulsatility is the mechanism, not a detail
The HPG axis responds to pulses. Continuous GnRH receptor stimulation famously does the opposite of intermittent stimulation — that is precisely how GnRH agonists are used to suppress testosterone in prostate cancer. Anything that flattens kisspeptin signalling into sustained elevation risks downregulating the axis rather than activating it.
// Mechanism of action
KISS1R (GPR54) agonism on GnRH neurons. Kisspeptin binds its receptor on hypothalamic GnRH neurons, triggering GnRH release into the portal circulation. This is the obligatory upstream step — without kisspeptin signalling, the axis does not start.
Downstream LH and FSH. GnRH stimulates pituitary release of luteinising hormone and follicle-stimulating hormone, which in turn drive gonadal testosterone or oestrogen production and gametogenesis.
Restoring pulsatility rather than replacing hormone. The theoretical appeal is identical to the argument for GH secretagogues over exogenous GH: stimulate the axis to do its own job, with feedback intact, instead of overriding it. Exogenous testosterone suppresses the axis; kisspeptin, in principle, drives it.
Central effects beyond reproduction. Human neuroimaging work reports kisspeptin modulating limbic activity in response to sexual and emotional stimuli — effects on attraction and mood processing that are not simply downstream of testosterone.[3]
Very rapid clearance. A four-minute half-life means a subcutaneous injection produces a sharp, brief spike. Kisspeptin-54 is longer-acting and is what several clinical protocols actually use — a distinction the research market does not always make.
01 Reported benefits
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Restores gonadotropin secretion in hypothalamic disorders [2]
Studied in hypothalamic amenorrhoea and hypogonadotropic hypogonadism, where the deficit is upstream and kisspeptin addresses it at the right level.
IVF ovulation trigger with lower OHSS risk [2]
Used as an alternative to hCG for oocyte maturation, with a reported reduction in ovarian hyperstimulation syndrome — a genuine clinical advantage in a real protocol.
Modulation of limbic responses to sexual and emotional stimuli [3]
Functional MRI work in men reports enhanced limbic activation and effects on mood processing, independent of downstream hormone change.
Investigated in hypoactive sexual desire [3]
Randomised human work has examined kisspeptin for low sexual desire in both men and women, with reported benefit on brain-activity and behavioural measures.
Very short half-life shapes the evidence [2]
Most human data uses intravenous infusion or the longer kisspeptin-54. Subcutaneous KP-10 bolus dosing — what the research market sells — is not what most studies did.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Raising testosterone without suppressing the axis
The dominant community use case: stimulate endogenous production rather than replace it. Mechanistically coherent and not demonstrated as a sustainable strategy — the axis adapts, and nobody has run it long enough to know how.
Post-cycle restoration of the HPG axis
Proposed as an upstream alternative to hCG or SERMs after androgen suppression. No trial has tested this.
Improved libido independent of testosterone [3]
Supported by the neuroimaging work, which is one of the more interesting findings in this library.
Concern: desensitisation with sustained exposure
The axis responds to pulses. Continuous or over-frequent stimulation risks receptor downregulation and the opposite of the intended effect — the same phenomenon that makes GnRH agonists suppressive.
Concern: unopposed oestrogen conversion
Driving endogenous testosterone raises the substrate for aromatisation. Nobody using this in the community is measuring oestradiol.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Increased libido within hours
The most consistent report, and it aligns with the central mechanism rather than requiring a testosterone rise.
Highly variable and inconsistent effects
Reported far more than for most compounds here — and exactly what a four-minute half-life administered subcutaneously would predict.
Transient rather than sustained
Effects reported as lasting hours, not days, which again matches the pharmacokinetics.
Diminishing effect with frequent dosing
Reported, and the single most mechanistically important community observation on this page — it is what desensitisation would look like.
Confusion between KP-10 and KP-54
Vendors sell kisspeptin-10; several key clinical protocols use kisspeptin-54, which behaves differently.
02 Adverse effects & risks
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Well tolerated in human studies [2]
Human trials including intravenous infusion report good tolerability with no significant adverse-event signal at studied doses.
No long-term human safety data
Studies are acute or short-course. Repeated self-administration over months has no characterisation.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
HPG axis desensitisation
The central risk, and directly analogous to a known and exploited pharmacological phenomenon. Over-frequent dosing plausibly achieves the opposite of the goal.
Oestradiol elevation
Follows from increased endogenous testosterone and aromatisation. Measurable; almost never measured.
Effects in hormone-sensitive conditions
Driving the reproductive axis in anyone with a hormone-sensitive condition is directionally concerning and unstudied.
Interaction with androgen or fertility therapy
Adding an upstream stimulus to established hormonal treatment is uncharacterised.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Few reported adverse effects
Consistent with the clinical tolerability data and with the very short exposure per dose.
Mild flushing or warmth
Occasionally reported shortly after injection.
No effect at all
Common, and unsurprising given the half-life and route mismatch.
03 Dosing ranges
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Intravenous infusion in most human studies [2]
Human work overwhelmingly uses continuous or bolus intravenous administration, often with kisspeptin-54 for longer-acting protocols. Dosing is typically weight-normalised.
No established subcutaneous dose
The route the research market uses is not the route most of the evidence used.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Infrequent dosing to preserve pulsatility
Given the desensitisation concern, less frequent is more defensible than more frequent — the opposite of the instinct most people apply.
Measure the axis rather than guess
LH, FSH, total and free testosterone and oestradiol are standard, inexpensive tests. This is one of the few compounds here where the intended effect is directly and cheaply measurable.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
100 mcg subcutaneous, as needed
A common community figure, typically used before activity rather than on a schedule.
200–500 mcg
Higher community range.
2–3× weekly rather than daily
Used specifically to avoid the reported diminishing effect — community practice arriving at the right answer for the right reason.
| Approach | Dose | Route | Frequency |
|---|---|---|---|
| Conservative | 100 mcg | Subcutaneous | 2–3× weekly |
| Standard | 200 mcg | Subcutaneous | 2–3× weekly |
| Higher-end | 500 mcg | Subcutaneous | As needed |
04 Synergy & interactions
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No research-peptide combination studies
None exists.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The same axis, driven the other way
Kisspeptin sits upstream of GnRH and switches the reproductive axis on. Leuprolide is a GnRH analogue given continuously, which downregulates the pituitary receptor and switches the axis off — used for prostate cancer, endometriosis, fibroids and central precocious puberty. Same pathway, opposite clinical intent, and the clearest demonstration available that the pituitary responds to the pattern of a signal rather than its presence.
With PT-141
Upstream endocrine stimulation alongside central melanocortin desire signalling — two different routes to overlapping outcomes.
Antagonism: exogenous testosterone
Exogenous androgen suppresses the HPG axis through negative feedback. Running it alongside an upstream stimulant is working against yourself, and it is the most common way this compound is wasted.
With GH secretagogues
Grouped together in the 15-Compound Matrix endocrine pillar. Different axes, no interaction data.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Neuro-cognitive and endocrine pillar of the 15-Compound Matrix
Grouped with Semax/Selank and the GH secretagogues.
05 Protocols
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
IVF ovulation trigger protocol [2]
Kisspeptin administered as an alternative to hCG for oocyte maturation, with reported reduction in OHSS risk — a defined clinical protocol.
Neuroimaging study design [3]
Randomised placebo-controlled crossover with intravenous kisspeptin during functional MRI and behavioural assessment.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Baseline and follow-up hormone panel
LH, FSH, total and free testosterone, oestradiol and SHBG. The effect is measurable, which makes not measuring it a choice.
Intermittent, not daily
The pulsatility argument, applied.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
2–3× weekly, as needed
The general community pattern.
Not part of the Gold Standard Protocol
It appears in the 15-Compound Matrix but not in the thirteen-compound protocol.
05b Condition-specific interest
Kisspeptin is the master switch of the reproductive axis, and it is one of the few compounds in this library whose human evidence comes from proper academic research rather than from suppliers. That research also used infusions in controlled settings, in a molecule whose half-life is measured in minutes — which is the gap between the papers and the vial.
No approval, no trial
Kisspeptin-10 is not approved anywhere. The human work is research-setting investigation, largely from a programme at Imperial College London, using intravenous infusion under monitoring. Native kisspeptin-10 has a half-life of a few minutes, so a subcutaneous bolus is a materially different exposure from the infusions that generated the data.
Study — randomised, small, published in a major journal
Hypoactive sexual desire disorder — in both sexes
Pathophysiology
Low sexual desire with associated distress. Unlike erectile dysfunction it is not primarily vascular, which is why vascular drugs do not address it.
Mechanistic rationale
Two randomised trials, in 32 premenopausal women and 32 men with HSDD, reported that kisspeptin administration boosted activity in brain structures of the sexual response network. In the men’s trial it also increased penile rigidity by up to 56% compared with placebo, and improved self-reported happiness about sex, with larger effects in men more distressed by their low desire. Small, proof-of-concept, and genuinely well conducted — which is a rare combination on this site.
Community reports
Community use for libido is growing on the strength of these trials. Note the design gap: those participants received monitored infusions, not a self-administered subcutaneous shot.
Components carrying the argument: KISS1R → GnRH → downstream, plus direct central effects
Study — human, and clinically interesting
Fertility and IVF — the safety advantage
Pathophysiology
In IVF, final oocyte maturation is triggered before retrieval, conventionally with hCG. Ovarian hyperstimulation syndrome is the major iatrogenic complication of the process, and hCG — with its long half-life and sustained LH-like activity — is a principal driver of it.
Mechanistic rationale
Kisspeptin triggers the body’s own LH surge rather than substituting a long-acting analogue for it, producing a more physiological and shorter-lived signal. Human studies have used it as an oocyte maturation trigger with a reduced risk of ovarian hyperstimulation syndrome, including in women at high risk. That is a genuine clinical advantage arising directly from the mechanism.
Community reports
Not a community use, and not one that could be. This is a monitored step within an IVF cycle timed to the hour.
Components carrying the argument: Endogenous LH surge, physiologically shaped
Theorized to study — the mechanism fits precisely
Functional hypothalamic amenorrhoea
Pathophysiology
In functional hypothalamic amenorrhoea, energy deficit, excessive exercise or psychological stress suppresses GnRH pulsatility. LH pulses fall, ovulation stops, and oestrogen deficiency follows — with bone loss as the consequence that outlasts the amenorrhoea.
Mechanistic rationale
Kisspeptin neurons are the integrating point where metabolic and stress signals reach the GnRH system, so this is the exact lesion kisspeptin sits upstream of, and administration has been shown to stimulate LH release in this population. But the suppression is a protective response to a real energy deficit, and overriding the signal pharmacologically without correcting the deficit restores a cycle in someone still under-fuelled. The bone loss is driven by the energy deficit as well as by the oestrogen.
Community reports
Discussed in athletic and RED-S contexts. The intervention with the evidence is restoring energy availability, and it is also the one that addresses the cause.
Components carrying the argument: KISS1R → GnRH pulse generation
Study — human genetics, definitive
Puberty and hypogonadotropic hypogonadism — how it was found
Pathophysiology
Puberty begins when GnRH pulsatility resumes after childhood quiescence. What controls that timing was unknown until the genetics answered it.
Mechanistic rationale
Loss-of-function mutations in KISS1R cause normosmic idiopathic hypogonadotropic hypogonadism — puberty does not start. Activating mutations cause central precocious puberty — it starts too early. That is about as clean a demonstration of a gene’s function in humans as endocrinology offers, and it is why kisspeptin is described as the master switch rather than as a contributor.
Community reports
Not a use case. It is the reason the compound is taken seriously as a research subject.
Components carrying the argument: KISS1R — human loss- and gain-of-function genetics
Theorized — upstream, and not a shortcut
Male hypogonadism and testosterone
Pathophysiology
Secondary hypogonadism reflects insufficient gonadotrophin drive. Exogenous testosterone suppresses that drive further and shuts down spermatogenesis, which is why it is the wrong treatment for anyone seeking conception.
Mechanistic rationale
Acting upstream at the kisspeptin level stimulates the axis rather than replacing its output, which is mechanistically attractive for preserving fertility. hCG and selective oestrogen receptor modulators already occupy that space with actual clinical use behind them. Kisspeptin also demonstrates the classic problem of upstream stimulation: continuous exposure desensitises the system, which is exactly what leuprolide exploits therapeutically at the next node down the axis.
Community reports
Used for testosterone and post-cycle purposes. Sustained dosing is the pattern most likely to produce the opposite of the intended effect.
Components carrying the argument: KISS1R, upstream of GnRH
Actionable
The pulsatility problem — and why the vial is not the trial
Pathophysiology
The entire reproductive axis is pulse-encoded. GnRH arrives in pulses, the pituitary responds to their frequency, and continuous exposure at any node desensitises the receptor rather than driving it harder.
Mechanistic rationale
Kisspeptin-10 has a half-life of minutes, and the human studies used controlled intravenous infusion, which allowed the exposure pattern to be shaped deliberately. A subcutaneous bolus is a different pharmacokinetic object entirely, and sustained or frequent dosing risks desensitising the receptor it is meant to stimulate. This library has three worked examples of the same principle — leuprolide, DAC versus no-DAC CJC-1295, and teriparatide versus continuous parathyroid hormone — and this is the fourth.
Community reports
Community protocols vary widely and are not derived from the research dosing, because the research dosing does not translate to a take-home injection.
Components carrying the argument: Pulsatility — the recurring principle in this library
| Application | Evidence | Setting studied | The thing to know |
|---|---|---|---|
| HSDD, men and women | Randomised, 32 + 32 | Research infusion | Penile rigidity up to +56% vs placebo |
| IVF oocyte trigger | Human studies | IVF cycle | Lower OHSS risk than hCG |
| Hypothalamic amenorrhoea | LH response shown | Research | Fix the energy deficit — it is the cause |
| Puberty / hypogonadism | Human genetics | — | KISS1R mutations define the axis |
| Male hypogonadism | Theorized | — | hCG and SERMs already occupy this space |
| Half-life | Minutes | — | Infusion ≠ subcutaneous bolus |
| Continuous exposure | — | — | Desensitises — see leuprolide |
What actually has evidence for these conditions
For low sexual desire: relationship and psychological factors first, then medication review — SSRIs are a very common and reversible cause. Treating depression, sleep disorder and alcohol use, and assessing testosterone where clinically indicated. Sex therapy has an evidence base and is under-used. Bremelanotide and flibanserin are approved for HSDD in premenopausal women.
For fertility: a workup on both sides of the couple before any intervention — semen analysis, ovulation assessment, tubal patency. Letrozole or clomifene for ovulation induction, gonadotrophins, IVF. In male secondary hypogonadism, testosterone suppresses spermatogenesis; hCG and SERMs exist precisely for that reason.
For functional hypothalamic amenorrhoea: restoring energy availability is the treatment — increased intake, reduced training load, and psychological support where an eating disorder is involved. This resolves the amenorrhoea and addresses the bone loss, which pharmacological cycle restoration alone does not.
06 Handling, reconstitution & storage
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Reconstitution
Supplied lyophilised, commonly 10 mg per vial. At 200 mcg per use a 10 mg vial covers fifty doses, which is a long in-use period at 2–3× weekly.
Storage
Lyophilised: −20 °C. Reconstituted: 2–8 °C.
Common vial sizes
Commonly 10 mg lyophilised vials.
Stability notes
Confirm whether you have kisspeptin-10 or kisspeptin-54 — they have materially different durations and much of the clinical literature uses the latter.
07 Legal & regulatory status
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Not approved for human use. Kisspeptin has an active and credible human research programme including clinical use as an IVF trigger in trial settings, but no marketing approval in any jurisdiction. Supplied as a research chemical.
Regulatory update — current as at August 2026
On 29 October 2024 the FDA's Pharmacy Compounding Advisory Committee voted against including Kisspeptin-10 on the Section 503A Bulks List. The committee cited a lack of evidence for clinical effectiveness and safety in the uses under review.
This was an earlier and separate round from the July 2026 meeting, and it is the part of the story that the coverage of that meeting almost entirely omits. Across two sittings in October and December 2024, PCAC considered seven substances — including ipamorelin, kisspeptin-10, AOD-9604, CJC-1295 and thymosin alpha-1 — and rejected every one of them. In July 2026 the same committee recommended six of the seven it looked at. What changed between the two rounds was the FDA's April 2026 restructuring of the Category 2 list and the set of substances nominated, not the arrival of new efficacy trials for anything on this page.
A negative advisory vote is not a ban and is not binding. It does mean there is no current 503A compounding pathway for this substance, and that a committee reviewing the evidence was not persuaded by it.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: the randomised HSDD trials in men and women. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Anti-doping
Agents affecting the hypothalamic-pituitary-gonadal axis fall under WADA S4 (hormone and metabolic modulators). Treat as prohibited.
§ Sources & further reading
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
- PubMed: KISS1R / GPR54 mutations and hypogonadotropic hypogonadism — the founding genetics (live query)Database or literature search
- PubMed: kisspeptin in humans — LH secretion, reproductive disorders and IVF trigger protocols (live query)Database or literature search
- PubMed: kisspeptin, limbic activity and sexual/emotional processing — Imperial College programme (live query)Database or literature search
Reminder
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.